BACKGROUND: Alloimmune lung injury, characterized by perivascular lymphocytic inflammation, lymphocytic bronchiolitis (LB), and obliterative bronchiolitis (OB), causes substantial morbidity and mortality after lung transplantation and bone marrow transplantation (BMT), but little is known regarding its pathogenesis. We have developed and pursued the hypothesis that local activation of pulmonary innate immunity through toll-like receptor (TLR)-4 is critical to the development of posttransplant alloimmune lung injury. METHODS: We developed a fully major histocompatibility complex-mismatched murine BMT model without systemic graft-versus-host disease, and challenged mice with aerosolized lipopolysaccharide (LPS), a prototypic TLR4 agonist, to determine the effect upon pulmonary alloimmune lung injury. RESULTS: LPS-exposed allogeneic BMT recipient mice developed histological and biological features of LB and OB, which were not observed in non-LPS-exposed allogeneic controls or syngeneic LPS-exposed mice. LPS-induced lymphocytic lung inflammation was dependent upon intact TLR4 signaling in donor-derived hematopoietic cells but not recipient structural lung cells, demonstrating a distinct function for TLR4 on hematopoietic cells in mediating alloimmunity. CONCLUSIONS: We demonstrate a critical role for localized, environmentally induced innate immune activation in promoting alloimmune lung injury. Local inhibition of TLR4 signaling in pulmonary resident hematopoietic cells represents a novel and potentially important therapeutic target to prevent posttransplant rejection.
BACKGROUND:Alloimmune lung injury, characterized by perivascular lymphocytic inflammation, lymphocytic bronchiolitis (LB), and obliterative bronchiolitis (OB), causes substantial morbidity and mortality after lung transplantation and bone marrow transplantation (BMT), but little is known regarding its pathogenesis. We have developed and pursued the hypothesis that local activation of pulmonary innate immunity through toll-like receptor (TLR)-4 is critical to the development of posttransplant alloimmune lung injury. METHODS: We developed a fully major histocompatibility complex-mismatched murine BMT model without systemic graft-versus-host disease, and challenged mice with aerosolized lipopolysaccharide (LPS), a prototypic TLR4 agonist, to determine the effect upon pulmonary alloimmune lung injury. RESULTS:LPS-exposed allogeneic BMT recipient mice developed histological and biological features of LB and OB, which were not observed in non-LPS-exposed allogeneic controls or syngeneic LPS-exposed mice. LPS-induced lymphocytic lung inflammation was dependent upon intact TLR4 signaling in donor-derived hematopoietic cells but not recipient structural lung cells, demonstrating a distinct function for TLR4 on hematopoietic cells in mediating alloimmunity. CONCLUSIONS: We demonstrate a critical role for localized, environmentally induced innate immune activation in promoting alloimmune lung injury. Local inhibition of TLR4 signaling in pulmonary resident hematopoietic cells represents a novel and potentially important therapeutic target to prevent posttransplant rejection.
Authors: Jordan D Savov; David M Brass; Barbara L Lawson; Erin McElvania-Tekippe; Julia K L Walker; David A Schwartz Journal: Am J Physiol Lung Cell Mol Physiol Date: 2005-04-15 Impact factor: 5.464
Authors: I P Neuringer; R B Mannon; T M Coffman; M Parsons; K Burns; J R Yankaskas; R M Aris Journal: Am J Respir Cell Mol Biol Date: 1998-09 Impact factor: 6.914
Authors: Steven M Fiser; Curtis G Tribble; Stewart M Long; Aditya K Kaza; John A Kern; David R Jones; Mark K Robbins; Irving L Kron Journal: Ann Thorac Surg Date: 2002-04 Impact factor: 4.330
Authors: Gerhard C Hildebrandt; Krystyna M Olkiewicz; Leigh A Corrion; Yayi Chang; Shawn G Clouthier; Chen Liu; Kenneth R Cooke Journal: Blood Date: 2004-04-06 Impact factor: 22.113
Authors: Scott M Palmer; Lauranell H Burch; Saad Mir; Stephen R Smith; Paul C Kuo; Walter F Herczyk; Nancy L Reinsmoen; David A Schwartz Journal: Clin Transplant Date: 2006 Jan-Feb Impact factor: 2.863
Authors: K R Cooke; G R Hill; J M Crawford; D Bungard; Y S Brinson; J Delmonte; J L Ferrara Journal: J Clin Invest Date: 1998-11-15 Impact factor: 14.808
Authors: Christine V Kinnier; Tereza Martinu; Kymberly M Gowdy; Julia L Nugent; Francine L Kelly; Scott M Palmer Journal: Transpl Immunol Date: 2010-11-09 Impact factor: 1.708
Authors: Tereza Martinu; Christine V Kinnier; Kymberly M Gowdy; Francine L Kelly; Laurie D Snyder; Dianhua Jiang; W Michael Foster; Stavros Garantziotis; John A Belperio; Paul W Noble; Scott M Palmer Journal: J Heart Lung Transplant Date: 2011-03-27 Impact factor: 10.247
Authors: Tereza Martinu; Kymberly M Gowdy; Julia L Nugent; Jesse Sun; Christine V Kinnier; Margaret E Nelson; Matthew A Lyes; Francine L Kelly; W Michael Foster; Michael D Gunn; Scott M Palmer Journal: Am J Respir Cell Mol Biol Date: 2014-12 Impact factor: 6.914
Authors: Kymberly M Gowdy; Julia L Nugent; Tereza Martinu; Erin Potts; Laurie D Snyder; W Michael Foster; Scott M Palmer Journal: Am J Respir Cell Mol Biol Date: 2011-09-29 Impact factor: 6.914
Authors: S Samuel Weigt; Ariss DerHovanessian; W Dean Wallace; Joseph P Lynch; John A Belperio Journal: Semin Respir Crit Care Med Date: 2013-07-02 Impact factor: 3.119
Authors: Vandy P Stober; Christopher Szczesniak; Quiana Childress; Rebecca L Heise; Carl Bortner; John W Hollingsworth; Isabel P Neuringer; Scott M Palmer; Stavros Garantziotis Journal: Am J Physiol Lung Cell Mol Physiol Date: 2014-04-18 Impact factor: 5.464